Thursday, April 27, 2017 1:22:45 PM
The article today even states this:
"With this pathway, the FDA uses animal efficacy studies and human safety data as the basis for product approval."
As we all know, there is only one safety study being conducted. Here is the study called: "A Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation"- Website:
https://clinicaltrials.gov/ct2/show/NCT03002519
The study will not be completed until 2019.
Everyone is talking about efficacy, and all of the papers confirm this focus and the great outcomes.. That data is sound. What is in question is how will humans respond to the pharmacodynamics of PLX-R18.
I hate to throw water on the flames, but this is a real fact that governments will require. Yes we will get bumps up along the way, but, in my humble opinion, we may be faced with a longer period of time until the safety data is satisfied.
Please don't all of you gang up on me at one time!!!
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM